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Objective: The peroxisome proliferator–activated receptor g activator pioglitazone has recently been reported to
possess pleiotropic cardioprotective and renoprotective actions. We hypothesized that pioglitazone would reduce
a dose of the immunosuppressant cyclosporine after heart transplantation, resulting in beneficial protective effects
for both cardiac allografts and recipient kidneys.
Methods: Experiments were performed by using an allomismatched rat heterotopic heart transplantation model.
Recipients were treated with cyclosporine with or without pioglitazone and were divided into one of 4 groups:
group I, no treatment; group II, low-dose cyclosporine (2 mg $ kg1 $ d1); group III, high-dose cyclosporine
(5 mg $ kg1 $ d1); and group IV, low-dose cyclosporine with pioglitazone (3 mg $ kg1 $ d1).
Results: Cyclosporine-treated rats showed significantly longer graft survival and less graft rejection but severe
renal damage in a dose-dependent manner. Compared with group II, treatment with pioglitazone with low-
dose cyclosporine (group IV) significantly suppressed graft infiltration of CD4/CD8 T lymphocytes and serum
concentrations of interleukin 2 and interferon g, leading to extended graft survival up to 60 days. These immu-
nosuppressive effects in group IV were equivalent to those in group III. In addition, recipient kidneys in group IV
had few apoptotic cells, possibly through upregulation of peroxisome proliferator–activated receptor g and down-
regulation of transforming growth factor b1, and maintained stable renal functions, as evidenced by a normaliza-
tion of blood urea nitrogen, creatinine, and creatinine clearance values. In vitro experiments also confirmed the
renoprotective effects of pioglitazone on cyclosporine-induced toxicity.
Conclusions: Collectively, pioglitazone can reduce a dose of cyclosporine with sufficient immunosuppressive
effects. Pioglitazone treatment with low-dose cyclosporine has synergistic protective effects for cardiac allografts
and recipient kidneys, leading to improvement of graft survival with a minimal cyclosporine-induced nephrotoxicity.
Cardiothoracic Transplantation Tanaka et alRecent advances in immunosuppressive agents have greatly
overcome acute graft rejection and improved both graft and
patient survival rates in heart transplantation.1,2 Calcineurin
inhibitors, such as cyclosporine (CsA), are first-line immuno-
suppressants widely used after transplantation and play an
important role for posttransplantation management. However,
the immense therapeutic potential of CsA is severely ham-
pered by CsA-induced nephrotoxicity.3,4 The toxic effect of
CsA is dose dependent, and therefore it is generally agreed
that close clinical monitoring of CsA levels is imperative to
optimize safety and efficacy in limiting the degree of renal
damage.5 In clinical settings immunosuppressive regimens
based on the association of low-dose CsA with other drugs,
such as mycophenolate mofetil, steroids, sirolimus, or everoli-
mus, have been recommended.6-8
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doi:10.1016/j.jtcvs.2009.04.019744 The Journal of Thoracic and Cardiovascular SurThiazolidinediones, which include the presently available
drug pioglitazone, are well-established insulin-sensitizing
agents that act as agonists of the ligand-activated transcrip-
tional factor peroxisome proliferator–activated receptor
(PPAR) g. It has recently been reported that pioglitazone
possesses pleiotropic cardioprotective9-11 and renoprotec-
tive12-14 actions in experimental settings, including anti-
inflammatory and antiproliferative properties. In the field
of heart transplantation, survival of cardiac allografts has
been prolonged by pioglitazone administration in experi-
mental mouse models15; however, the mechanisms and
renoprotective effects have not been fully elucidated.
Although pioglitazone has protective effects to limit renal
damage caused by CsA in nonsurgical models,16 there are
no reports of pioglitazone in reference to the dose reduction
of CsA in heart transplantation.
Taken together, the aim of this study was to evaluate
whether pioglitazone has a potential to reduce the dose of
CsA for renal protection with immunosuppressive effects
in heart transplantation.
MATERIALS AND METHODS
Animals
Forty-eight inbred male rats 16 weeks of age and weighing 280 to 300 g
were used in the present study. Lewis (RT1) and Brown Norway (RTn) ratsgery c September 2009
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XAbbreviations and Acronyms
BUN ¼ blood urea nitrogen
CsA ¼ cyclosporine
IFN ¼ interferon
IL ¼ interleukin
PPAR ¼ peroxisome proliferator–activated
receptor
TGF ¼ transforming growth factor
TUNEL ¼ transferase-mediated dUTP-biotin
nick end labeling
were obtained from Charles River Japan (Yokohama, Japan). The handling
of laboratory animals and their use in experiments conformed to the
‘‘Guidelines for animal experimentation’’ at Kobe University Graduate
School of Medicine (Permission number: P080306) and the ‘‘Guide for
the care and use of laboratory animals’’ published by the US National Insti-
tutes of Health (publication no. 85-23, revised 1996).
Drugs
Pioglitazone was provided by Takeda Chemical Industries (Tokyo,
Japan). CsA (Sandimmune) was purchase from Novartis Pharmaceuticals
(Tokyo, Japan). Pioglitazone diluted in normal saline was administered to
recipient mice by means of gastric gavage, and CsA was administered sub-
cutaneously.
Rat Heart Transplantation Model
Major allomismatched rat heterotopic heart transplantation was per-
formed as described by Ono and Lindsey.17 Brown Norway rats were
used as donors, and Lewis rats were used as recipients. The aorta and pul-
monary artery of the donor heart were anastomosed to the recipient’s
abdominal aorta and inferior vena cava, respectively. During the observa-
tion period, graft rejection or survival was gauged by means of daily manual
palpitation. Body weight of the recipient rats was measured once a week.
Experimental Groups
Rats were randomly divided into one of 4 groups as follows: group I
received no treatment as a control, group II received low-dose CsA (2 mg
$ kg1 $ d1), group III received high-dose CsA (5 mg $ kg1 $ d1), and
group IV received low-dose CsA (2 mg $ kg1 $ d1) with pioglitazone (3
mg $ kg1 $ d1). In the present study 2 experiments were performed:
a 1-week end point experiment (n ¼ 6 in each group) and a survival exper-
iment (n¼ 6 in each group). Drugs were administered once a day beginning
3 days before heart transplantation and lasting until the 1-week end point of
the experiment or a beating cessation of cardiac allografts.
Specimen Preparation
Graft hearts and recipient kidneys were harvested and rinsed in saline
and fixed in 10% formalin. The formalin-fixed grafts were dehydrated in
a graded ethanol bath, cleaned in xylene, embedded in paraffin, and sec-
tioned (thickness, 4 mm) for histologic analysis.
Histology
Graft sections were stained with hematoxylin and eosin. The severity of
graft rejection was graded by using a modified form of the Working Formu-
lation of the International Society for Heart and Lung Transplantation cri-
teria18,19: 0, no rejection; 1, interstitial infiltration, perivascular infiltration,
or both of mononuclear cells without myocyte damage; 2, one focal infil-
tration of mononuclear cells with associated myocyte damage; 3, multifocalThe Journal of Thoracic and Cor diffuse infiltration of mononuclear cells with myocyte damage; and 4,
multifocal or diffuse infiltration of mononuclear and polymorphous cells
with extensive myocyte damage. Histopathologic evaluation was per-
formed by an experienced observer (T.H.) who was blinded to the treatment
protocol.
Immunohistochemical Staining
Immunohistochemical staining was performed with mouse anti-rat mono-
clonal antibodies against CD4 and CD8 (BD PharMingen, San Diego, Calif)
with biotin-labeled anti-mouse immunoglobulin (Vector Laboratories, Burlin-
game, Calif). The Vectastain ABC kit (Vector Laboratories) was used to detect
positive cells according to the manufacturer’s instructions. Diaminobenzidine
substrate (DakoCytomation, Carpinteria, Calif) was used as a chromogen, and
cell nuclei were counterstained with hematoxylin. Positive cell numbers were
quantified by counting immunoreactive cells in 10 nonoverlapping high-
power fields by using the National Institutes of Health image program (version
1.63; National Institutes of Health, Bethesda, Md).
Transferase-Mediated dUTP-Biotin Nick End
Labeling Staining
Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end
labeling (TUNEL) staining was performed with the In Situ Cell Death De-
tection Kit (Roche Applied Science, Indianapolis, Ind) to detect apoptosis in
situ. Methods for the counterstaining of cell nuclei and the quantification of
TUNEL-positive cells were the same as those for immunohistochemical
staining.
Immunofluorescent Staining
Immunofluorescent staining was performed with primary antibodies:
mouse monoclonal anti–PPAR-g antibody, rabbit polyclonal anti–trans-
forming growth factor (TGF) b1 antibody, and anti-Bax antibodies (Santa
Cruz Biotechnology, Santa Cruz, Calif). Fluorescein-linked sheep anti-
mouse antibody and donkey anti-rabbit antibody were used as secondary
antibodies (Amersham Biosciences, Buckinghamshire, United Kingdom).
The cell nuclei were counterstained with 40,6-diamidino-2-phenylindole
(Chemicon International, Temecula, Calif).
Renal Function
Blood urea nitrogen (BUN) and creatinine levels in plasma and urine
were measured with commercial assay kits (BUN-test-Wako and Creati-
nine-test-Wako, respectively; Wako Pure Chemicals, Osaka, Japan),
according to the manufacturer’s instructions. The glomerular filtration rate
was calculated as creatinine clearance by using the standard formula UV/
P, where U is urinary creatinine (in milligrams per deciliter), V is urine vol-
ume (in milliliters per minute), and P is plasma creatinine (in milligrams per
deciliter). At 1 week after transplantation, 24-hour urine was collected from
each rat housed in a metabolic cage.
Quantification of Interleukin 2, Interferon g, and
TGF-b1
Concentrations of interleukin (IL) 2, interferon (IFN) g, and TGF-b1
were measured by means of enzyme-linked immunosorbent assay with
Quantikine Rat immunoassay kits (R&D Systems, Minneapolis, Minn),
according to the manufacturer’s instructions.
Statistics
Database management and statistical analysis were performed with Stat-
view version 5.0 software (SAS institute, Inc, Cary, NC). All values are
expressed as means  standard errors of the mean for the number of mice
or independent analyses. Kaplan–Meier analysis was performed to evaluateardiovascular Surgery c Volume 138, Number 3 745
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test. Comparisons among groups were performed with the nonparametric
Mann–Whitney U test.
RESULTS
Pioglitazone Reduced CsA Dose With an
Improvement of Allograft Survival
We first confirmed an effect of CsA on the allograft
survival in our rat heart transplantation model. CsA signifi-
cantly prolonged the survival period in a dose-dependent
manner (group I vs group II, P ¼ .0014; group II vs group
III, P¼ .0007). There were no dropouts of recipient mice be-
fore the beating cessation of cardiac allograft in each group.
Next we investigated the effect of pioglitazone treatment
with low-dose CsA (group IV) on the allograft survival.
Compared with group II, the graft survival in group IV
was dramatically extended up to 60 days (P ¼ .0018). The
survival period in group IV was equivalent to that in group
III (Figure 1). During the survival observation in group IV,
we did not find any pioglitazone-related side effects, such as
fluid retention, congestive heart failure, fractures, and hepa-
tocellular injury. There were no significant differences in
body weight change among each group after transplantation.
Suppression of Acute Allograft Rejection
At 1 week after transplantation, diffuse infiltration of
mononuclear or polymorphous cells with associated cardi-
omyocyte damage was present in most areas of cardiac al-
lografts in group I. CsA significantly decreased the
rejection scores and the numbers of infiltrating CD4þ and
CD8þ cells in a dose-dependent manner. By means of pio-
glitazone treatment with low-dose CsA, far less cellular in-
filtration and a lack of cardiomyocyte damage was present
in group IV compared with that seen in group II. There
FIGURE 1. Effects of pioglitazone and cyclosporine on allograft survival
in our rat heart transplantation model. *P< .005. Pio, Pioglitazone; CsA,
cyclosporine A; NS, not significant. Data were analyzed by using a log-
rank test of Kaplan–Meier analysis.746 The Journal of Thoracic and Cardiovascular Surwere no significant differences between groups III and IV
(Figure 2).
Reduction of Serum IFN-g and IL-2 Levels
Because suppression of IL-2 and IFN-g levels offers a bio-
logic response to CsA,20,21 we measured serum levels of IL-2
and IFN-g at 1 week after transplantation. At 1 week after
transplantation, CsA treatment significantly decreased those
levels in a dose-dependent manner. Compared with group II,
pioglitazone treatment with low-dose CsA (group IV) signifi-
cantly decreased serum IL-2 and IFN-g levels, and there were
no significant differences in those in group III (Figure 3).
Protection of Renal Function
Because plasma BUN and creatinine levels are ordinary
markers of functional nephrotoxic damage to the kidney,
we measured these levels and evaluated creatinine clearance.
At 1 week after transplantation, CsA treatment significantly
increased plasma levels of BUN and creatinine and de-
creased creatinine clearance in a dose-dependent manner.
This CsA-induced renal dysfunction was suppressed by pio-
glitazone treatment with low-dose CsA (Figure 4).
Suppression of Renal Apoptosis
At 1 week after transplantation, TUNEL-stained sections
showed that CsA significantly increased the number of
TUNEL-positive cells in a dose-dependent manner. By
means of pioglitazone treatment with low-dose CsA, far
less apoptotic renal cells were present in group IV compared
with numbers seen in groups II and III (Figure 5). To further
confirm the renal apoptosis, we performed immunofluores-
cent staining of Bax, which is one of the key components
for cell-induced apoptosis. Although CsA treatment in-
creased renal Bax expression in a dose-dependent manner,
the CsA-induced Bax upregulation was apparently sup-
pressed by pioglitazone treatment with low-dose CsA.
Regulation of Renal PPAR-g and TGF-b1 Expression
Immunofluorescent staining has shown that pioglitazone
treatment upregulates PPAR-g expression in the recipient
kidneys at 1 week after transplantation (Figure 6, A). Be-
cause TGF-b1 plays a pivotal role in the development of
CsA nephropathy,22 we next evaluated TGF-b1 protein ex-
pression in the recipient kidneys by means of enzyme-linked
immunosorbent assay, as well as by means of immunofluo-
rescent staining. Although CsA treatment significantly in-
creased renal TGF-b1 expression in a dose-dependent
manner, the CsA-induced TGF-b1 stimulation was signifi-
cantly suppressed by pioglitazone treatment with low-dose
CsA (Figure 6).
DISCUSSION
To the best our knowledge, the present study provides the
first evidence that the PPAR-g agonist pioglitazone cangery c September 2009
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XFIGURE 2. Histologic findings of cardiac allografts in acute rejection. A, Hematoxylin and eosin (HE) staining and immunohistochemical staining of CD4
and CD8. Bar¼ 100 mm. B, Rejection score. C, Quantitative analysis of CD4þand CD8þcells. NS, Not significant. All data are expressed as means standard
errors of the mean.
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immunosuppressive effects in rat heart transplantation. In
a nonsurgical setting Pereira and colleagues16 have recently
reported that pioglitazone limits CsA nephrotoxicity, possi-
bly because of a downregulation of plasminogen activator
inhibitor 1 and an overexpression of the regulatory factor
Smad7 in rats. The study evaluated rat renal function, such
as serum creatinine values, and CsA nephrotoxicity, such
as arteriopathy, in the 28-day treatment. Although our study
could not evaluate such a chronic CsA nephrotoxicity be-
cause of the survival of CsA-treated cardiac allografts, we
have evaluated recipient renal function and apoptosis in de-
tail at 1 week after heart transplantation. The major findings
of the present study are that pioglitazone treatment in asso-
ciation with low-dose CsA leads to (1) prolongation of car-
diac allograft survival similar to that seen with conventional
high-dose CsA treatment and (2) significant attenuation of
CsA-induced nephrotoxicity (possibly through upregulation
of PPAR-g and downregulation of TGF-b1) in a rat heart
transplantation model. Because renal failure caused by
CsA treatment is one of the serious problems occurring after
transplantation of nonrenal organs,4 the dose reduction of
CsA caused by the combination of pioglitazone could bring
beneficial effects in patients with heart transplantations.
FIGURE 3. Serum concentrations of interleukin 2 (IL-2; A) and interferon
g (IFN-g; B) by means of enzyme-linked immunosorbent assay. NS, Not
significant. All data are expressed as means  standard errors of the mean.748 The Journal of Thoracic and Cardiovascular SuFIGURE 4. Effects of pioglitazone and cyclosporine on recipient renal
function: A, serum BUN levels; B, serum creatinine levels; and C, creatinine
clearance. NS, Not significant. All data are expressed as means  standard
errors of the mean.rgery c September 2009
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XFIGURE 5. Histologic findings of renal apoptosis after heart transplantation. A, transferase-mediated dUTP-biotin nick end labeling (TUNEL) staining and
immunofluorescent staining of Bax. TUNEL-positive cells (brown) are shown by arrows. Intracellular expression of Bax is identified by the green emission.
Cell nuclei are identified by the blue emission. Bar¼ 100 mm. B, Quantitative analysis of TUNEL-positive cells. All data are expressed as means standard
errors of the mean.
FIGURE 6. Renal expression of peroxisome proliferator–activated receptor g (PPAR-g) and transforming growth factor b1 (TGF-b1) after heart transplan-
tation. A, Immunofluorescent staining of PPAR-g and TGF-b1. Intracellular expression of PPAR-g and TGF-b1 is identified by the green emission. Cell
nuclei are identified by the blue emission. Bar ¼ 100 mm. B, TGF-b1 protein levels in recipient kidney, as determined by means of enzyme-linked immu-
nosorbent assay. NS, Not significant. All data are expressed as means  standard errors of the mean.
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pression in the recipient kidneys. Previous in vitro experiments
have also shown that pioglitazone treatment increases mRNA
expression and activity of PPAR-g in renal cells.23 Recently,
several experimental studies demonstrated that PPAR-g acti-
vation with thiazolidinediones has protective effects against
both heart24-26 and kidney27,28 disorders, including anti-in-
flammatory and antiproliferative properties. Therefore there
are obvious potential benefits of graft protection and renopro-
tection induced by PPAR-g activation with pioglitazone.
The present study showed that CsA administration re-
sulted in dose-dependent nephrotoxicity, as evidenced by
a significant increase in plasma BUN and creatinine levels,
and a significant reduction in creatinine clearance at 1
week after transplantation. These renal functional distur-
bances were further confirmed by means of histopathologic
findings, such as apoptosis in glomerular and tubular epithe-
lial cells. In recent years, renal cell apoptosis has been pro-
posed as a putative primary pathomechanism that might
underlie progression of chronic renal disease, including
nephrosclerosis.29,30 In the present study pioglitazone treat-
ment combined with low-dose CsA significantly amelio-
rated both functional and histopathologic damage in
recipient kidneys. Based on these findings, we suggest that
pioglitazone can provide good renoprotection against CsA-
induced nephrotoxicity.
TGF-b is a multifunctional cytokine that plays an impor-
tant role as one of the major pathogenic factors in fibrotic
changes in kidney diseases.31 It was reported that CsA
administration induces histologic and functional alterations
of the kidney parallel with an increase in TGF-b1 levels.22,32
In the present study renal TGF-b1 levels were upregulated
by CsA treatment in a dose-dependent manner. However,
pioglitazone treatment with low-dose CsA significantly sup-
pressed the upregulation of TGF-b1 compared with high-
dose CsA treatment or low-dose CsA alone. Recently,
PPAR-g activation was reported to inhibit TGF-b expres-
sion, resulting in the suppression of neointima forma-
tion.33,34 In addition, TGF-b can closely induce apoptotic
signaling in renal cells.29 The suppression of TGF-b1 signal-
ing might be a key mechanism for pioglitazone-induced
renoprotection against CsA nephrotoxicity.
As expected, the current study demonstrates that the cal-
cineurin inhibitor CsA decreased serum levels of IL-2 and
IFN-g in a dose-dependent manner. Because both IL-2
and IFN-g are rejection products in activated lymphocytes,
they are both good markers of the pharmacodynamic immu-
nosuppressive effects of CsA.20,21 Moreover, thiazolidine-
dione was recently reported to mediate inhibition of IL-2
or IFN-g secretion.15,35 Successful posttransplantation im-
munosuppression must balance the suppression of graft
rejection with a minimal CsA nephrotoxicity. At this point,
pioglitazone with low-dose CsA is a suitable regimen for
immunosuppressive treatment during heart transplantation750 The Journal of Thoracic and Cardiovascular Surbecause we have shown that pioglitazone with low-dose
CsA provided (1) less graft rejection than high-dose CsA
and (2) less renal damage than high-dose CsA. Interestingly,
the protective effects of pioglitazone with low-dose CsA
were greater than those of low-dose CsA alone. We believe
that the synergistic effects of pioglitazone and low-dose CsA
lead to both graft protection and renoprotection against
CsA-induced nephrotoxicity.
Although pioglitazone has some clinical drawbacks, such
as causing fluid retention, congestive heart failure, fractures,
and hepatocellular injury, we firmly believe that pioglita-
zone has numerous advantages as long as the dose is
optimal. In accordance with the previous report,36 we ad-
ministered the same dose (3 mg $ kg1 $ d1) of pioglitazone
in this study without those adverse effects. In clinical set-
tings various immunosuppressive regimens based on the
association of low-dose CsA with other drugs are adopted
during posttransplantation management. For example, ste-
roids are also important immunosuppressive agents in addi-
tion to CsA in organ transplantation. However, they have the
potential to increase the incidence of infection, and steroid
withdrawal can result in an increase of posttransplantation
coronary artery disease.37 Pioglitazone might be a major
alternative to steroids because of its pharmacologic kinetics.
This study presents some limitations that deserve
acknowledgement. The first limitation is that experiments
were performed with a rat heterotopic nonworking heart
transplantation model. Although this model has been widely
accepted as a standard experimental model of heart transplan-
tation, there are some discrepancies between the model and
clinical heart transplantation with regard to species, non-
working heart, and heterotopic transplantation. Therefore
the beneficial effects of pioglitazone on immune response
and renal function in the present study might be an extrapo-
lation from a nonclinically relevant rat model to clinical hu-
man heart transplantation. Further studies are needed to
determine the accurate effects of pioglitazone on both cardiac
allografts and recipient kidneys during heart transplantation.
The second limitation is that the present study has not
established the dose-response or time-response relation
between pioglitazone and CsA with regard to either the
reduction of cardiac rejection or the renal toxicity of CsA.
Because these relations might be very narrow, the lack of
these relations could invalidate the clinical relevance in the
present study.
The final limitation is represented by the lack of mRNA
analysis, such as real-time polymerase chain reaction, to
evaluate renal expression of signal pathways in pioglitazone
treatment.
In conclusion, pioglitazone treatment with low-dose CsA
leads to synergistic protective effects for cardiac allografts and
recipient kidneys. Pioglitazone has a potential use for immuno-
suppressive regimens based on the combination with low-dose
CsA, providing minimal CsA-induced nephrotoxicity.gery c September 2009
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